ライフサイエンスコーパス: bone scintigraphy

1 isease sites at conventional imaging (CT and bone scintigraphy).

2 All patients received baseline bone scintigraphy.

3 crasia with evidence of myocardial uptake on bone scintigraphy.

4 om poor responders on (68)Ga-PSMA PET/CT and bone scintigraphy.

5 phosphono-1,2-propanodicarboxylic-acid (DPD) bone scintigraphy.

6 T/CT and whole-body MRI were performed after bone scintigraphy.

7 ntitative expression of tumor burden seen on bone scintigraphy.

8 the referring physician and did not undergo bone scintigraphy.

9 oms with focal abnormalities on conventional bone scintigraphy.

10 iography, computed tomographic scanning, and bone scintigraphy.

11 ase bone scintigraphy and combined leukocyte/bone scintigraphy.

12 x of the patients also underwent three-phase bone scintigraphy.

13 %, respectively, compared to 91% and 55% for bone scintigraphy.

14 esulted in unusually extensive photopenia on bone scintigraphy.

15 %, respectively, compared to 88% and 77% for bone scintigraphy.

16 for radiographic skeletal survey compared to bone scintigraphy.

17 red with a combination of whole-body MRI and bone scintigraphy (95.7% vs. 91.6%, P = 0.17, 87.6% vs.

18 %, P < 0.001, 89.8% vs. 74.7%, P = 0.01) and bone scintigraphy (96.2% vs. 64.6%, P < 0.001, 89.8% vs.

19 m)technetium dicarboxypropane diphosphonate (bone scintigraphy), (99m)technetium mercaptoacetyltrigly

20 of bone metabolism is dominated by gamma-ray bone scintigraphy: a technique in which gamma-ray emissi

21 Bone scintigraphy accurately diagnoses osteomyelitis in

22 metastases were studied with both 99mTC MDP bone scintigraphy and 18FDG PET, and the number of lesio

23 Results of bone scintigraphy and biochemical investigations were an

24 tions of patients having been referred after bone scintigraphy and cardiac magnetic resonance imaging

25 ve imaging methods such as echocardiography, bone scintigraphy and cardiovascular MRI.

26 his series, was superior to both three-phase bone scintigraphy and combined leukocyte/bone scintigrap

27 on models including the visual assessment of bone scintigraphy and other relevant covariates.

28 The annual use of bone scintigraphy and radiotracer therapies was unchange

29 rade 2 or 3 myocardial radiotracer uptake on bone scintigraphy and the absence of a monoclonal protei

30 ninvasive diagnosis with the combined use of bone scintigraphy and the exclusion of a monoclonal prot

31 terpreted images from CT, whole-body MRI, or bone scintigraphy and were blinded to results with the o

32 Of these, 12 patients also had bone scintigraphy and whole-body MRI within a 1- to 5-wk

33 pared the results with those for (99m)Tc-MDP bone scintigraphy and whole-body MRI.

34 iography and ATTR-CA by myocardial uptake on bone scintigraphy and/or positive endomyocardial biopsy

35 , and negative conventional imaging (CT plus bone scintigraphy) and MRI results for patients with PSA

36 Study procedures included CT, bone scintigraphy, and (68)Ga-PSMA PET/CT at baseline, a

37 ety of these patients underwent radionuclide bone scintigraphy, and 70 patients underwent brain CT or

38 , chest computed tomography scan, liver MRI, bone scintigraphy, and axial skeleton MRI have been prov

39 T findings were correlated with those of CT, bone scintigraphy, and biopsy.

40 body PET was more accurate than thoracic CT, bone scintigraphy, and brain CT or MR imaging in staging

41 Computed tomography, bone scintigraphy, and lumbar spine x-rays were performe

42 vidual comparison) using (68)Ga-PSMA-11 PET, bone scintigraphy, and MRI.

43 severity as measured by both radiograph and bone scintigraphy, and synovial fluid IL-1beta was assoc

44 Four underwent bone scintigraphy, and two underwent gallium scintigraph

45 CT and bone scintigraphy are not useful for response evaluation

46 imaging, including radiographs, CT, MRI, and bone scintigraphy, are recognized as being insensitive a

47 indicator and support further exploration of bone scintigraphy as an imaging biomarker in CRMPC.

48 ming various imaging examinations, including bone scintigraphy as well as CT and MRI of the lumbosacr

49 18)F-FDG PET/CT, CT, renal scintigraphy, and bone scintigraphy at 41 (49%), 27 (32%), 25 (30%), and 1

50 To perform evaluation of widely embraced bone scintigraphy-based non-biopsy diagnostic criteria (

51 All had negative conventional CT and bone scintigraphy before enrollment.

52 o-1,2-propanodicarboxylic-acid ((99m)Tc-DPD) bone scintigraphy between 2010 and 2020 were included.

53 ative assessment of skeletal tumor burden on bone scintigraphy (Bone Scan Index [BSI]) in patients wh

54 rates of overuse defined as combined use of bone scintigraphy (BS) and PET, which current guidelines

55 er (MBC) by (18)F-FDG PET instead of (99m)Tc bone scintigraphy (BS) supports clinically relevant chan

56 tomography/computed tomography (PET/CT) and bone scintigraphy (BSc) in women with suspected MBC.

57 dred consecutive young athletes referred for bone scintigraphy by a sports medicine clinic because of

58 2 (W12) in addition to conventional imaging (bone scintigraphy, CT) at baseline and W12 were retrospe

59 fluorodeoxyglucose (FDG) PET/CT or at CT and bone scintigraphy (CTBS), and to compare patterns of loc

60 f metaphyseal osteomyelitis in a child where bone scintigraphy demonstrated photopenia of the distal

61 cinoma of the gall bladder is rare and hence bone scintigraphy does not form a part of the routine wo

62 MR alone and CT and MR combined with bone scintigraphy enable the accurate detection of stage

63 Bone scintigraphy enables the diagnosis of cardiac ATTR

64 tic resonance [MR] imaging, radiography, and bone scintigraphy) findings in three adolescent boys wit

65 resonance imaging but differed for those of bone scintigraphy, follow-up skeletal survey, spinal mag

66 chemical failure had negative NaF PET/CT and bone scintigraphy for bone metastases.

67 isease, replace technetium-99m diphosphonate bone scintigraphy for osteomedullary metastasis assessme

68 Background CT and bone scintigraphy have limitations in evaluating systemi

69 or subsequent SACT based on standard CT and bone scintigraphy imaging.

70 treotide, and Tc-99m-methylene diphosphonate bone scintigraphy in 30 patients with SDHB-associated PG

71 progressive disease (PD) earlier than CT and bone scintigraphy in bone-only MBC.

72 that of a combination of whole-body MRI and bone scintigraphy in patients with breast and prostate c

73 We have compared 18FDG PET with 99mTc MDP bone scintigraphy in patients with skeletal metastases f

74 ardiography, cardiac magnetic resonance, and bone scintigraphy in the assessment of functional and ce

75 18FDG PET is superior to bone scintigraphy in the detection of osteolytic breast

76 taken with the aim of evaluating the role of bone scintigraphy in the diagnosis and staging of LCH.

77 predictive value but is less sensitive than bone scintigraphy in the identification of osseous metas

78 r study to ascertain the diagnostic value of bone scintigraphy in this disease.

79 y, supporting the hypothesis that whole-body bone scintigraphy is a means of quantifying the total-bo

80 chnetium methylene diphosphonate (99mTc MDP) bone scintigraphy is currently the method of choice for

81 Bone scintigraphy may have a role in monitoring a patien

82 aphy (n = 26), computed tomography (n = 12), bone scintigraphy (n = 15), and magnetic resonance (MR)

83 aphics and images from radiography (n = 36), bone scintigraphy (n = 17), angiography (n = 4), compute

84 If neither conventional bone scintigraphy nor NaF PET were available, referring

85 tablished criteria (ie, proven with positive bone scintigraphy or endomyocardial biopsy).

86 nventional CT, appropriately supplemented by bone scintigraphy or other modalities), was defined pros

87 s to patients with findings confirmed by CT, bone scintigraphy, or biopsy or considered highly likely

88 yethylene-diphosphonate ((99m)Tc-HDP) planar bone scintigraphy (pBS), (99m)Tc-HDP SPECT/CT, (18)F-NaF

89 phosphono-1,2-propanodicarboxylic acid (DPD) bone scintigraphy (Perugini grade 0: negative; grades 1

90 nderwent ATTR screening by blinded 99mTc-DPD bone scintigraphy (Perugini Grade-0 negative, 1-3 increa

91 Bone scintigraphy receiver operating characteristic curv

92 ed to identify CA prevalence and outcomes in bone scintigraphy referrals.

93 Bone scintigraphy remains the most commonly used imaging

94 Bone scintigraphy remains the standard, but the specific

95 o-phase (soft-tissue and delayed) whole-body bone scintigraphy results in appropriate diagnosis and t

96 gh-risk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.

97 light chain amyloidosis when interpreting a bone scintigraphy scan assessing for transthyretin cardi

98 5 to 2021; evaluations included radionuclide bone scintigraphy, serum and urine immunofixation, sFLC

99 Bone scintigraphy studies were reviewed and graded accor

100 Radiographic skeletal surveys and whole-body bone scintigraphy study results were reviewed for all pa

101 disease severity as determined by late-phase bone scintigraphy, supporting the hypothesis that whole-

102 ascular MRI with tissue characterization and bone scintigraphy to diagnose cardiac amyloidosis has re

103 long been recognized that technetium-labeled bone scintigraphy tracers can localize to myocardial amy

104 resonance imaging and cardiac repurposing of bone scintigraphy tracers.

105 ging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy.

106 Bone scintigraphy using (99m)Tc-labeled methylene diphos

107 myopathies, myocardial radiotracer uptake on bone scintigraphy was >99% sensitive and 86% specific fo

108 2014 and October 2015 and for whom baseline bone scintigraphy was available.

109 Progressive disease at bone scintigraphy was evident in only half of participan

110 7 [54%], P=0.003), whereas cardiac uptake on bone scintigraphy was less common in AApoAIV-CA than AAp

111 Three-phase bone scintigraphy was positive in all six neuropathic jo

112 PD at bone scintigraphy was reported in 50% of participants (1

113 Bone scintigraphy was sensitive (1.0) but nonspecific (0

114 In case of PD, bone scintigraphy was used to assess for bone disease pr

115 taneous manifestations, for which whole-body bone scintigraphy (WBBS) is frequently used in diagnosis

116 ylene diphosphonate ((99m)Tc-MDP) whole-body bone scintigraphy (WBBS) with reported RPE.

117 ng to our pediatric radiology department for bone scintigraphy were evaluated.

118 Findings at bone scintigraphy were positive in all lesions.

119 ostate cancer) referred for standard-of-care bone scintigraphy were prospectively enrolled in this st

120 tate cancer with negative findings on CT and bone scintigraphy were referred for (18)F-DCFPyL (2-(3-(

121 and therapeutic radiopharmaceutical use and bone scintigraphy were unchanged.

122 CT, MR, and bone scintigraphy were used to evaluate tumor stage.

123 ith unexplained hypercalcemia who under went bone scintigraphy, which demonstrated marked tracer upta

124 he results were also compared with available bone scintigraphy, white blood cell scintigraphy, and (1

125 - or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy.

126 Bone scintigraphy with SPECT can help identify patients

127 Group A patients underwent bone scintigraphy with SPECT prior to injection.

128 osive sacroiliitis at pelvic radiography and bone scintigraphy with technetium 99m ((99m)Tc) methylen

129 roiliitis at pelvic radiography (Fig 1A) and bone scintigraphy with technetium 99m methylene diphosph

130 If NaF PET were unavailable, conventional bone scintigraphy would have been ordered in 85% of pati